Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 13, 2018

SELL
$46.25 - $104.45 $326,062 - $736,372
-7,050 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$57.4 - $108.44 $404,670 - $764,502
7,050 New
7,050 $749,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $223M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Lisanti Capital Growth, LLC Portfolio

Follow Lisanti Capital Growth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lisanti Capital Growth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lisanti Capital Growth, LLC with notifications on news.